Victory Capital Management Inc. Buys 7,833 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Victory Capital Management Inc. grew its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 742,871 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,833 shares during the period. Victory Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $23,163,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Commonwealth Equity Services LLC raised its stake in shares of Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after acquiring an additional 350 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the last quarter. Covestor Ltd raised its stake in shares of Supernus Pharmaceuticals by 15.3% during the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 358 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after buying an additional 600 shares during the last quarter.

Insider Activity

In related news, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company’s stock, valued at $303,236. The trade was a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 over the last quarter. 9.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SUPN has been the subject of a number of recent research reports. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Stock Down 0.9 %

Supernus Pharmaceuticals stock opened at $35.25 on Tuesday. The stock has a market capitalization of $1.95 billion, a PE ratio of 32.94 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The company has a 50 day moving average of $33.38 and a 200-day moving average of $30.96.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.29) earnings per share. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.